A Phase 1 study of the long‐acting anti‐IL‐5 monoclonal antibody GSK3511294 in patients with asthma

AIMS: GSK3511294 is a humanized anti‐interleukin (IL)‐5 monoclonal antibody (mAb) engineered for extended half‐life and improved IL‐5 affinity versus other anti‐IL‐5 mAbs. This study examined its safety, tolerability, pharmacokinetics (PK) and effect on blood eosinophil counts. METHODS: This was a d...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Dave, Fuhr, Rainard, Bird, Nicholas P., Mole, Sarah, Hardes, Kelly, Man, Yau Lun, Cahn, Anthony, Yancey, Steven W., Pouliquen, Isabelle J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290054/
https://www.ncbi.nlm.nih.gov/pubmed/34292606
http://dx.doi.org/10.1111/bcp.15002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290054/
https://www.ncbi.nlm.nih.gov/pubmed/34292606
http://dx.doi.org/10.1111/bcp.15002

Ejemplares similares